Drug Dollars Seek to Convince Doctors That 2nd Choice Is OK
This article is for subscribers only.
U.S. doctors and hospitals received more than $20 million last year in payments related to AstraZeneca Plc’s diabetes drug Bydureon, more than for any other medication, newly released company disclosures show.
Drugmakers spent more than $10 million in 2014 on each of 10 different drugs through cash payments and items of value given to U.S. doctors and hospitals, according to a Bloomberg compilation of the data released Tuesday by a U.S health agency. The payments include consulting and speaking fees, honoraria, meals and travel expenses associated with marketing or educating doctors about a drug.